{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:25Z","timestamp":1792441765237,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40121-024-00933-2","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:02:23Z","timestamp":1709287343000},"page":"565-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Nicholas","family":"Rebold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alosaimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Dionne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Taqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhamid","family":"Lagnf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Eudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica V.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley D.","family":"Kufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"D\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Frens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Geriak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Delaportas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Larew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"933_CR1","volume-title":"Vancomycin: a comprehensive review of 30 years of clinical experience","author":"GL Cooper","year":"1986","unstructured":"Cooper GL, Given DB. Vancomycin: a comprehensive review of 30 years of clinical experience. Park Row Publishing Incorporated A Wiley and Sons Medical Group Comp; 1986."},{"key":"933_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2097","author":"GP Ramos-Otero","year":"2022","unstructured":"Ramos-Otero GP, Sarangarm P, Walraven C. A retrospective analysis of intravenous vs oral antibiotic step-down therapy for the treatment of uncomplicated streptococcal bloodstream infections. J Clin Pharmacol. 2022. https:\/\/doi.org\/10.1002\/jcph.2097.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"933_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cmi.2019.05.012","volume":"26","author":"MN Al-Hasan","year":"2020","unstructured":"Al-Hasan MN, Rac H. Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections. Clin Microbiol Infect. 2020;26(3):299\u2013306.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"933_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425\u201336.","journal-title":"N Engl J Med"},{"key":"933_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312","author":"K Iversen","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N England J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1808312.","journal-title":"N England J Med"},{"issue":"5","key":"933_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/phar.2389","volume":"40","author":"M Krsak","year":"2020","unstructured":"Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review. Pharmacotherapy. 2020;40(5):469\u201378.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"933_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","volume":"24","author":"R Agarwal","year":"2018","unstructured":"Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"23","key":"933_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169\u201379.","journal-title":"N Engl J Med"},{"issue":"1","key":"933_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ofid\/ofx163.800","volume":"4","author":"C Bryson-Cahn","year":"2017","unstructured":"Bryson-Cahn C, Beieler A, Chan J, Senter S, Harrington R, Dhanireddy S. A little bit of dalba goes a long way: dalbavancin use in a vulnerable patient population. Open Forum Inf Dis. 2017;4(1):336\u20137.","journal-title":"Open Forum Inf Dis"},{"key":"933_CR10","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2147\/DDDT.S313756","volume":"15","author":"M Gatti","year":"2021","unstructured":"Gatti M, Andreoni M, Pea F, Viale P. <p>real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs<\/p>. DDDT. 2021;15:3349\u201378.","journal-title":"DDDT"},{"issue":"1","key":"933_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40121-021-00568-7","volume":"11","author":"PL Gonzalez","year":"2022","unstructured":"Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW. Outcomes in patients with Staphylococcus aureus bacteremia treated with dalbavancin in clinical trials. Infect Dis Ther. 2022;11(1):423\u201334.","journal-title":"Infect Dis Ther"},{"key":"933_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","volume":"81","author":"S Wunsch","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210\u20134.","journal-title":"Int J Infect Dis"},{"key":"933_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","volume":"18","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18:30.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"933_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331","author":"U Rappo","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Inf Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofy331.","journal-title":"Open Forum Inf Dis"},{"key":"933_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106210","author":"MP Veve","year":"2020","unstructured":"Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard of care for outpatient treatment of invasive Gram-positive infections. Int J Antimicrob Agents. 2020. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106210.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"933_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis. 2018;67(5):795\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"933_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmacy10010001","volume":"10","author":"K Antosz","year":"2022","unstructured":"Antosz K, Al-Hasan MN, Lu ZK, et al. Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care. Pharmacy. 2022;10(1):1.","journal-title":"Pharmacy"},{"key":"933_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac335","author":"KC Molina","year":"2022","unstructured":"Molina KC, Lunowa C, Lebin M, et al. Comparison of sequential dalbavancin to standard-of-care treatment for Staphylococcus aureus bloodstream infections. Open Forum Inf Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofac335.","journal-title":"Open Forum Inf Dis"},{"key":"933_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12941-022-00507-5","volume":"21","author":"C Evins","year":"2022","unstructured":"Evins C, Lancaster H, Schnee AE. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series. Ann Clin Microbiol Antimicrob. 2022;21:16.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"933_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/427283","volume":"40","author":"I Raad","year":"2005","unstructured":"Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374\u201380.","journal-title":"Clin Infect Dis"},{"key":"933_CR21","unstructured":"AbbVie (2022) Phase 2, Open-label, randomized, multicenter study to compare the efficacy and safety of dalbavancin to standard of care antibiotic therapy for the completion of treatment of patients with complicated bacteremia or documented infective endocarditis. clinicaltrials.gov"},{"issue":"4","key":"933_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"933_CR23","doi-asserted-by":"publisher","first-page":"e02260","DOI":"10.1128\/AAC.02260-20","volume":"65","author":"PG Cojutti","year":"2021","unstructured":"Cojutti PG, Rinaldi M, Zamparini E, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with Staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2021;65(5):e02260-e2320.","journal-title":"Antimicrob Agents Chemother"},{"key":"933_CR24","unstructured":"Baklouti S, Marolleau S, Chavanet P, Bonnet E, Concordet, Gandia P (2021) Letter to the Editor on: \u201cPopulation pharmacokinetics of dalbavancin and dosing considerations for optimal treatment of adult patients with Staphylococcal osteoarticular Infections\u201d. Antimicrob Agents Chemother. Published online October 18, 2021:AAC.01493-21"},{"key":"933_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab486","author":"MM Cooper","year":"2021","unstructured":"Cooper MM, Preslaski CR, Shihadeh KC, Hawkins KL, Jenkins TC. Multiple-dose dalbavancin regimens as the predominant treatment of deep-seated or endovascular infections: a scoping review. Open Forum Inf Dis. 2021. https:\/\/doi.org\/10.1093\/ofid\/ofab486.","journal-title":"Open Forum Inf Dis"},{"issue":"3","key":"933_CR26","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u201355.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"933_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"3","key":"933_CR28","first-page":"074","volume":"7","author":"EF Eaton","year":"2020","unstructured":"Eaton EF, Westfall AO, McClesky B, et al. In-hospital illicit drug use and patient-directed discharge: barriers to care for patients with injection-related infections. Open Forum Inf Dis. 2020;7(3):074.","journal-title":"Open Forum Inf Dis"},{"key":"933_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","volume":"23","author":"NA Turner","year":"2022","unstructured":"Turner NA, Zaharoff S, King H, et al. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials. 2022;23:407.","journal-title":"Trials"},{"key":"933_CR30","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID) (2021) Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): a phase 2b, multicenter, randomized, open-label, assessor-blinded superiority study to compare the efficacy and safety of dalbavancin to standard of care antibiotic therapy for the completion of treatment of patients with complicated S. aureus Bacteremia. clinicaltrials.gov"},{"issue":"1","key":"933_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jcpt.12580","volume":"43","author":"JM Steele","year":"2018","unstructured":"Steele JM, Seabury RW, Hale CM, Mogle BT. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. J Clin Pharm Ther. 2018;43(1):101\u20133.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"933_CR32","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","volume":"24","author":"BJ Werth","year":"2018","unstructured":"Werth BJ, Jain R, Hahn A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018;24(4):429.e1-429.e5.","journal-title":"Clin Microbiol Infect"},{"key":"933_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","volume":"7","author":"M Kussmann","year":"2018","unstructured":"Kussmann M, Karer M, Obermueller M, et al. Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect. 2018;7:202.","journal-title":"Emerg Microbes Infect"},{"key":"933_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac341","author":"R Zhang","year":"2022","unstructured":"Zhang R, Polenakovik H, Barreras Beltran IA, et al. Emergence of dalbavancin, vancomycin, and daptomycin non-susceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization. Clinl Inf Dis. 2022. https:\/\/doi.org\/10.1093\/cid\/ciac341.","journal-title":"Clinl Inf Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00933-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T16:29:18Z","timestamp":1711470558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00933-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00933-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicholas Rebold, Jeffery C. Pearson, Brandon Dionne, Ahmad Taqi, Abdalhamid Lagnf, Kristen Lucas, Mark Biagi, Nicholas Lombardo, Joshua Eudy, Daniel T. Anderson, Joseph A. D\u2019Antonio, Jeremy J Frens, Tyler Baumeister, Matthew Geriak, Dino Delaportas, Jeremy Larew, and Michael P. Veve have no conflicts of interest to report. Sara Alosaimy is a current employee of Seres Therapeutics. Monica V. Mahoney has received funds for research from Merck; consulting funds from Cidara, Melinta, Merck, Pfizer, Qpex, and Spero; speaker honoraria from Paratek. Wesley D. Kufel has received research grants from Merck and Melinta; served on the advisory board for Theratechnologies, Inc.; Bruce M. Jones has received funds for consulting or participated in speaking bureaus for AbbVie, Melinta, Merck, Paratek, and La Jolla. George Sakoulas has consulted for Octapharma, AbbVie, and Paratek Pharmaceuticals and is on the speakers bureau for AbbVie and Paratek Pharmaceuticals. Dimitrios Farmakiotis has received research support from Astellas, Viracor and Merck, and consultation fee from Viracor. Michael J. Rybak has received funds for research and consulting or participated in speaking bureaus for AbbVie, Ferring, Melinta, Merck, Paratek Pharmaceuticals, Shionogi, Spero, La Jolla, and T2 Bioscience and was\/is partially supported by National Institute of Allergy and Infectious Diseases R01 AI121400 and R21 AI163726. Michael J. Rybak is Editor in Chief of Infectious Diseases and Therapy. Michael J. Rybak\u00a0was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.\u00a0All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Approval was obtained from Wayne State University (#012019MP2E), Henry Ford Hospital (#14715), and all of the contributing medical centers with a waiver for informed consent due to the retrospective nature of the study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}